Business
AffyXell expands partnership with GenScript ProBio
AffyXell expands partnership with GenScript ProBio.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \n \n 16 May 2022\n \n \n \n \n \n \n \n \n Avacta Group plc\n \n \n \n \n \n \n \n \n (\"Avacta\" or \"the Group\" or \"the Company\")\n \n \n \n \n \n \n \n \n AffyXell expands its strategic partnership with GenScript ProBio\n \n \n \n \n \n \n \n \n \n AffyXell, Avacta's joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies\n \n \n \n \n \n \n \n \n \n GenScript ProBio agrees to take an equity stake in AffyXell as a strategic investor at next funding round\n \n \n \n \n \n \n Avacta Group plc (AIM: AVCT),\n a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that AffyXell, its joint venture with South Korean drug maker Daewoong Pharmaceutical, has expanded its strategic partnership with GenScript ProBio, a leading biopharmaceutical manufacturer.\n \n \n \n \n \n AffyXell is a joint venture established in January 2020 by Daewoong Pharmaceutical and Avacta, d\n evelop\n ing\n the next generation of\n cell and gene\n therapies\n based on mesenchymal stem cells\n which incorporate Affimer\n \n ®\n \n immunotherapies\n .\n This\n new class of\n stem cell therapy\n is\n designed\n to produce\n \n Affimer® proteins, in situ in the body, that\n reduc\n e\n inflammatory or autoimmune responses\n to the stem cell therapy to potentially enhance their therapeutic effects\n .\n \n \n \n \n \n GenScript ProBio, part of Genscript Biotech Corporation (HKG: 1548), is a leading global contract development and manufacturing organisation providing a best-in-class, one-stop platform for research and development of biological drugs, DNA plasmids and lentiviruses, and for clinical production of cell and gene therapy products.\n \n \n \n \n \n AffyXell and GenScript ProBio are extending their strategic manufacturing partnership, which they entered into in December 2021, that covers AffyXell's first drug development programme to include additional future programmes. The partnership covers\n process\n development and production of viral vectors required for the production of AffyXell's future cell therapy products. In addition, as part of this strategic alliance, GenScript has now comm...